Document is current
Any future updates will be listed below
-
Authors
Fillbrunn, Mirko
Signorovitch, James
André, Fabrice
Wang, Iris
Lorenzo, Ines
Ridolfi, Antonia
Park, Jinhee
Dua, Akanksha
Rugo, Hope S.
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals
- License Information
-
More Information
Article History
Received: 28 October 2021
Accepted: 5 September 2022
First Online: 21 September 2022
Declarations
:
: Not applicable.
: Not applicable.
: Mirko Fillbrunn, James Signorovitch, and Akanksha Dua are employees of Analysis Group, Inc. a consulting firm that received funding from Novartis Pharmaceuticals for the conduct of this research.Fabrice Andre reports grants from Novartis during the conduct of this study and grants from AstraZeneca, Pfizer, Eli Lilly, Roche, Daiichi outside the submitted work.Iris Wang, Ines Lorenzo, Antonia Ridolfi, Jinhee Park are employees of Novartis and may own stock options.Hope S. Rugo reports grants from Pfizer, Merck, Novartis, Lilly, Genentech, OBI, Odonate, Daiichi, Eisai, Seattle Genetics, Macrogenics and Immunomedics, other from Samsung, and advisory boards for Puma and Celtrion, other from Daiichi, Mylan, Pfizer, Merck, AstraZeneca, Novartis and Macrogenics, during the conduct of the study.
